Ascentage Pharma Group International (AAPG)
NASDAQ: AAPG · Real-Time Price · USD
26.56
-0.77 (-2.82%)
Apr 8, 2026, 10:31 AM EDT - Market open
AAPG Employees
Ascentage Pharma Group International had 767 employees as of December 31, 2025. The number of employees increased by 200 or 35.27% compared to the previous year.
Employees
767
Change
200
Growth
35.27%
Revenue / Employee
$107,018
Profits / Employee
-$231,657
Market Cap
2.40B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 767 | 200 | 35.27% |
| Jun 30, 2025 | 605 | - | - |
| Dec 31, 2024 | 567 | -16 | -2.74% |
| Dec 31, 2023 | 583 | 3 | 0.52% |
| Dec 31, 2022 | 580 | -33 | -5.38% |
| Dec 31, 2021 | 613 | 180 | 41.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Sarepta Therapeutics | 835 |
| Adaptive Biotechnologies | 624 |
| Beam Therapeutics | 511 |
| Celldex Therapeutics | 198 |
| Immunome | 177 |
| Disc Medicine | 155 |
| Kodiak Sciences | 124 |
AAPG News
- 11 days ago - Full Year 2025 Ascentage Pharma Group International Earnings Presentation Transcript - GuruFocus
- 13 days ago - Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates - GlobeNewsWire
- 21 days ago - Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026 - GlobeNewsWire
- 4 weeks ago - Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026 - GlobeNewsWire
- 5 weeks ago - Ascentage Pharma Group International is Now Oversold (AAPG) - Nasdaq
- 2 months ago - Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 - GlobeNewsWire
- 2 months ago - Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 months ago - ASH 2025 | Updated Data for Ascentage Pharma's Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment - Benzinga